Skip to main content
SpringerLink
Log in

Metabolic Profile of Indapamide Sustained-Release in Patients with Hypertension

Data from Three Randomised Double-Blind Studies

  • Original Research Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Objective: To evaluate the influence of indapamide sustained-release (SR) 1.5 mg/day, a thiazide-related sulfonamide diuretic, on serum levels of lipids (total cholesterol, high-density lipoprotein-cholesterol, low-density lipoprotein-cholesterol and triglycerides), glucose and uric acid, and renal function (serum urea and creatinine levels).

Methods: Pooled data from three randomised, double-blind, controlled studies are analysed. Two of these studies were of short duration (2 and 3 months), one of which included a 9-month nonblind extension phase, and the third was a 12-month prospective study. Short- and long-term metabolic effects of the treatment could thus be analysed. All studies were conducted in patients with mild-to-moderate hypertension; the total population randomised in these studies comprised 1195 patients, of whom 505 had left ventricular hypertrophy (LVH).

Results: After 2 to 3 months’ treatment with indapamide SR 1.5 mg/day, there was no significant change from baseline in serum lipid levels and glucose levels. This neutral effect was maintained after 9 and 12 months of treatment. Renal function was not affected by short- or long-term indapamide SR 1.5 mg/day therapy. Serum uric acid level was slightly increased after short-term therapy, but was restored to baseline values during long-term therapy with indapamide SR 1.5 mg/day.

Conclusions: Indapamide SR 1.5 mg/day has no deleterious effect on glucose metabolism, serum levels of lipids and uric acid, or renal function. This antihypertensive agent can be considered to be an attractive therapeutic choice for all patients with mild-to-moderate hypertension, including the elderly and patients with increased cardiovascular risks, i.e. those with LVH.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V

Similar content being viewed by others

References

  1. Sytkowski PA, Kannel WB, D’Agostino RB. Changes in risk factors and the decline in mortality from cardiovascular disease. The Framingham Heart Study. N Engl J Med 1990; 322: 1635–41

    Article  PubMed  CAS  Google Scholar 

  2. Levy D, Wilson PW, Anderson KM, et al. Stratifying the patient at risk from coronary disease: new insights from the Framingham Heart Study. Am Heart J 1990; 119: 712–7

    Article  PubMed  CAS  Google Scholar 

  3. Kannel WB, Larson M. Long-term epidemiologic prediction of coronary disease. The Framingham experience. Cardiology 1993; 82: 137–52

    Article  PubMed  CAS  Google Scholar 

  4. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-VI). Arch Intern Med 1997; 157: 2413–46

    Article  Google Scholar 

  5. World Health Organization Guidelines Subcommittee. International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999; 17: 151–83

    Google Scholar 

  6. MRC Working Party. search Council trial of treatment of hypertension in older adults: principal results. BMJ 1992; 304: 405–12

    Article  Google Scholar 

  7. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255–64

    Article  Google Scholar 

  8. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827–38

    Article  PubMed  CAS  Google Scholar 

  9. Dahlöf B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish trial in old patients with hypertension (STOP-Hypertension). Lancet 1991; 338: 1281–5

    Article  PubMed  Google Scholar 

  10. Preuss HG, Bums JF. Adverse metabolic effects of antihypertensive drugs: implications for treatment. Drug Saf 1996; 14: 355–64

    Article  PubMed  CAS  Google Scholar 

  11. Ferrari P, Rosman J, Weidmann P. Antihypertensive agents, serum lipoproteins and glucose metabolism. Am J Cardiol 1991;67: 26B-35B

    Article  Google Scholar 

  12. Ames RP. The effects of antihypertensive drugs on serum lipids and lipoproteins, I: diuretics. Drugs 1986; 32: 260–78

    Article  PubMed  CAS  Google Scholar 

  13. Murphy MB, Lewis PJ, Kohner E, et al. Glucose intolerance in hypertensive patients treated with diuretics, a 14-year follow-up. Lancet 1982; II: 1293–5

    Article  Google Scholar 

  14. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989; 321: 868–3

    Article  PubMed  CAS  Google Scholar 

  15. Ramsay LE, Yeo WW, Jackson PR. Influence of diuretics, calcium antagonists, and α-blockers on insulin sensitivity and glucose tolerance in hypertensive patients. J Cardiovasc Pharmacol 1992; 20 (Suppl. 11): S49–54

    Article  PubMed  Google Scholar 

  16. Grimm M, Weidmann P, Meier A, et al. Correction of altered noradrenaline reactivity in essential hypertension by indapamide. Br Heart J 1981; 46: 404–9

    Article  PubMed  CAS  Google Scholar 

  17. Finch L, Hicks PE, Moore RA. Changes in vascular reactivity in experimental hypertensive animals following treatment with indapamide. J Pharm Pharmacol 1977; 29: 739–43

    Article  PubMed  CAS  Google Scholar 

  18. Campbell DB, Taylor AR, Hopkins YW, et al. Pharmacokinetics and metabolism of indapamide: a review. Curr Med Res Opin 1977; 5 Suppl 1: 13–24

    Article  Google Scholar 

  19. Campbell DB, Brackman F. Cardiovascular protective properties of indapamide. Am J Cardiol 1990; 65: 11H–27H

    Article  PubMed  CAS  Google Scholar 

  20. Chaffman M, Heel RC, Brogden RN, et al. Indapamide: a review of its pharmacodynamic properties and therapeutic efficacy in hypertension. Drugs 1984; 28: 189–235

    Article  PubMed  CAS  Google Scholar 

  21. Senior R, Imbs JL, Bory M, et al. Indapamide reduces hypertensive left ventricular hypertrophy: an international multicenter study. J Cardiovasc Pharmacol 1993; 22: 106–10

    Google Scholar 

  22. Carey PA, Sheridan DJ, de Cordoüe A, et al. Effect of indapamide on left ventricular hypertrophy in hypertension: a meta-analysis. Am J Cardiol 1996; 77: 17B-9B

    Article  Google Scholar 

  23. Leonetti G, Rappelli A, Salvetti A, et al. Long-term effects of indapamide: final results of a 2-year Italian multicenter study in systemic hypertension. Am J Cardiol 1990; 65: 67H–71H

    Article  PubMed  CAS  Google Scholar 

  24. Raggi U, Palumbo P, Moro B, et al. Indapamide in the treatment of hypertension in non-insulin-dependent diabetes. Hypertension 1985; 7: 11157–60

    Article  Google Scholar 

  25. Ames R. A comparison of blood lipid and blood pressure responses during the treatment of systemic hypertension with indapamide and with thiazides. Am J Cardiol 1996; 77: 12B–6B

    Article  PubMed  CAS  Google Scholar 

  26. Weidmann P, Boehlen LM. Arterial hypertension in diabetes. In: Alberti KGMM, Zimmet P, DeFronzo RA, et al., editors. International textbook of diabetes mellitus. 2nd ed. Chichester, UK: John Wiley & Sons Ltd, 1997

    Google Scholar 

  27. Ambrosioni E, Safar M, Degaute JP, et al. on behalf of the European Study Group. Low-dose antihypertensive therapy with 1.5 mg sustained-release indapamide: results of randomized double-blind controlled studies. J Hypertens 1998; 16: 1677–84

    Article  PubMed  CAS  Google Scholar 

  28. Mallion JM, Asmar R, Boutelant S, et al. Twenty-four hour antihypertensive efficacy of indapamide, 1.5-mg sustained release: results of two randomized double-blind controlled studies. J Cardiovasc Pharmacol 1998; 32: 673–8

    Article  PubMed  CAS  Google Scholar 

  29. Laubie M, Schmitt H. Comparison of the haemodynamic and autonomic effects of furosemide and indapamide and localization of the natriuretic action of indapamide. Curr Med Res Opin 1977; 5 Suppl 1: 89–100

    Article  CAS  Google Scholar 

  30. Schiavi P, Jochemsen R, Guez D. Pharmacokinetics of sustained- and immediate-release formulations of indapamide after single and repeated oral administration in healthy volunteers. Fundam Clin Pharmacol 2000; 14: 139–46

    Article  PubMed  CAS  Google Scholar 

  31. Asmar R, Amah G, Crisan O, et al. Efficacy and tolerance of indapamide sustained release 1.5 mg on 24-h blood pressure in essential hypertension. Eur Heart J Suppl 1999; 1 (Suppl. P): P21–30

    CAS  Google Scholar 

  32. Gosse P, Guez D, Gueret P, et al. Centralized echocardiogram quality control in a multicenter study of regression of left ventricular hypertrophy in hypertension. J Hypertens 1998; 16(4): 531–5

    Article  PubMed  CAS  Google Scholar 

  33. Gosse P, Sheridan DJ, Zannad F, et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. J Hypertens 2000; 18(10): 1465–75

    Article  PubMed  CAS  Google Scholar 

  34. Gosse P, Guéret P, Dubourg O, et al. How left ventricular geometry pattern influences left ventricular hypertrophy regression in hypertensive patients over 1 year: the LIVE study [abstract]. J Hypertens 2000; 18 Suppl 2: S149

    Google Scholar 

  35. Moser M. Do different hemodynamic effects of antihypertensive drugs translate into different safety profiles? Eur J Clin Pharmacol 1990; 38: S134–8

    Article  PubMed  CAS  Google Scholar 

  36. Fletcher A, Amery A, Birkenhager W, et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. J Hypertens 1991; 9: 225–30

    Article  PubMed  CAS  Google Scholar 

  37. Harper R, Ennis CN, Sheridan B, et al. Effect of low dose versus conventional dose thiazide diuretic on insulin action in essential hypertensives. BMJ 1994; 309: 226–30

    Article  PubMed  CAS  Google Scholar 

  38. Savage PJ, Pressel SL, Curb JD, et al. on behalf of the SHEP Cooperative Research Group. Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension. Arch Intern Med 1998; 158: 741–51

    Article  PubMed  CAS  Google Scholar 

  39. Pickkers P, Schachter M, Hughes AD, et al. Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels? Diabetologia 1996; 39: 861–4

    Article  PubMed  CAS  Google Scholar 

  40. McVeigh GE, Dulie EB, Ravenscroft A, et al. Low and conventional dose cyclo-penthiazide on glucose and lipid metabolism in mild hypertension. Br J Clin Pharmacol 1989; 27: 523–6

    Article  PubMed  CAS  Google Scholar 

  41. Carlsen RE, Kober L, Torp-Pedersen C, et al. Relation between dose of bendrofluazide, antihypertensive effect and adverse biochemical effects. BMJ 1990; 300: 975–8

    Article  PubMed  CAS  Google Scholar 

  42. Leonetti G, Rappelli A, Salvetti A, et al. Tolerability and well-being with indapamide in the treatment of mild-moderate hypertension: an Italian multicenter study. Am J Med 1988; 84: 59–64

    PubMed  CAS  Google Scholar 

  43. Aubert I, Djian F, Rouffy J. Beneficial effects of indapamide on lipoproteins and apoproteins in ambulatory hypertensive patients. Am J Cardiol 1990; 65: 77H–80H

    Article  PubMed  CAS  Google Scholar 

  44. Teuscher AU, Weidmann PU. Requirements for antihypertensive therapy in diabetic patients: metabolic aspects. J Hypertens 1997; 15: S67–75

    CAS  Google Scholar 

  45. Harrower AD, McFarlane G. Antihypertensive therapy in diabetic patients: the use of indapamide. Am J Med 1988; 84: 89–91

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The study was supported by Servier, Courbevoie, France.

Author information

Authors and Affiliations

  1. University of Bern, Bern, Switzerland

    Peter Weidmann

Authors
  1. Peter Weidmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Weidmann, P. Metabolic Profile of Indapamide Sustained-Release in Patients with Hypertension. Drug-Safety 24, 1155–1165 (2001). https://doi.org/10.2165/00002018-200124150-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200124150-00006

Keywords

Search

Navigation